期刊文献+

噻唑烷二酮类对2型糖尿病患者骨密度的影响 被引量:3

下载PDF
导出
摘要 目的探讨噻唑烷二酮类药物对2型糖尿病患者骨密度的影响,以便在临床应用该药时尽量避免其副反应。方法选择2型糖尿病患者150名分为对照组和实验组各75例,对照组服用二甲双胍或格列本脲,实验组在对照组基础上,加服噻唑烷二酮类药物。结果经过治疗12个月后,观察比较两组患者骨密度情况。显示出实验组患者的骨密度比对照组明显降低,两组数据相比较差异有非常显著性(P<0.05)。结论噻唑烷二酮类药物可改善2型糖尿病代谢紊乱,但存在降低患者骨密度的风险,临床是应用该药物时,尽可能要多方面考虑。
作者 王静
出处 《中国医药指南》 2012年第23期612-613,共2页 Guide of China Medicine
  • 相关文献

参考文献5

  • 1王振基,申竹芳.噻唑烷二酮类不良反应研究进展[J].中国新药杂志,2005,14(11):1364-1366. 被引量:14
  • 2Kahn SE,Haffner SM,Heise MA,et al.Glycemic durability of rosiglitazone,metformin,or Glyburide monotherapy[J].N Engl J Med,2006,355(23):2427-2443.
  • 3Home PD,Pocock SJ,Beck-Nielsen H,et al.Rosiglitazone evaluated for cardiovascular outcomes in oral agentcombination therapy for type 2 diabetes (RECORD):A multicentre,randomised,open-label trial[J].Lancet,2009,373(9861):609-633.
  • 4Rzonca SO,Suva LJ,Caddy D,et a1.Bone is a target for the antidiabetic compound rosiglitazone[J].Endocrinology,2004,145(1):401-406.
  • 5侯建明,李建卫,林庆明,陈文新,庄维特,蔡穗珍,张超群,林丽香.2型糖尿病合并外周血管病变患者的骨密度变化[J].中国医师进修杂志(内科版),2006,29(11):46-48. 被引量:10

二级参考文献22

  • 1Ott P, Ranek L, Young MA. Pharmacokinetics of troglitazone, a PPAR-γ agonist, in patients with hepatic insufficiency[J]. Eur J Clin Pharmacol, 1998,54(7): 567 - 571.
  • 2Bonkovsky HL, Azar R, Bird S, et al. Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone[J] . Dig Dis Sci ,2002, 47(7): 1632 -1637.
  • 3May LD, Lefkowitch JH, Kram MT, et al. Mixed hepatocellularcholestatic liver injury after pioglitazone therapy [ J ]. Ann Intern Med, 2002, 136(6): 449-452.
  • 4Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association [J]. Diabetes Care, 2004, 27(1):256-263.
  • 5Mori Y, Murakawa Y, Okada K, et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients [ J ]. Diabetes Care,1999, 22(6) :908 - 912.
  • 6Song J, Knepper MA, Hu X, et al. Rosiglitazone activates renal sodium-and water-reabsorptive pathways and lower blood pressure in normal rats[J]. J Pharmacol Exp Ther, 2004, 308(2): 426 - 433.
  • 7Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications[J]. Endocr Pruct, 2003, 9(5): 406 - 416.
  • 8Buch HN, Baskar V, Barton DM, et al. Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes[J]. Diabet Med, 2002,19(7): 572 - 574.
  • 9Lygate CA, Hulbert K, Monfared M, et al. The PPARgammaactivator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction [ J ]. Cardiovasc Res,2003,58(3) :632 - 637.
  • 10Tan M, Johns D, Gonzalez GG, et al. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized,double-blind, parallel-group trial [ J ]. Clin Ther, 2004, 26 ( 5 ):680 - 693.

共引文献22

同被引文献30

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部